Skip to main content
Beijing SL Pharmaceutical Co., Ltd. logo

Beijing SL Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002038 ISIN · CNE000001L31 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,472 across all filing types
Latest filing 2018-03-19 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 002038

About Beijing SL Pharmaceutical Co., Ltd.

https://www.slpharm.com.cn

Beijing SL Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and commercialization of pharmaceutical products. The company focuses on several therapeutic areas, including cardiovascular and cerebrovascular diseases, oncology, and infectious diseases. Its product portfolio features a range of chemical drugs and active pharmaceutical ingredients (APIs), with key offerings such as clopidogrel bisulfate and amlodipine besylate. Operating with advanced production facilities that adhere to international Good Manufacturing Practice (GMP) standards, the company emphasizes technological innovation and quality control. The organization serves both domestic and international markets, leveraging its integrated R&D platform to develop generic medications and innovative formulations aimed at improving patient outcomes.

Recent filings

Filing Released Lang Actions
监事会对公司2017年内部控制评价报告的意见
Audit Report / Information Classification · 95% confidence The document is an opinion from the Supervisory Board on the company's 2017 internal control evaluation report. It references regulatory guidelines related to internal control and disclosure requirements. The content focuses on the internal control system's effectiveness and the Supervisory Board's review and opinion on the internal control self-evaluation report. It does not contain full financial statements or detailed financial performance data, nor is it an announcement of a report publication. This type of document aligns with an Audit Report / Information (AR) category, which includes audit reports, applied accounting principles, and internal control evaluations separate from full annual reports. FY 2017
2018-03-19 Chinese
内部控制规则落实自查表
Regulatory Filings Classification · 95% confidence The document is titled as an "内部控制规则落实自查表" which translates to "Internal Control Rules Implementation Self-Inspection Form." It contains detailed internal control checklists related to internal audit operations, information disclosure controls, insider trading controls, fundraising controls, related party transactions, external guarantees, major investments, and other important matters. The document is a self-assessment or internal control checklist rather than a financial report or announcement. It does not contain financial statements, earnings data, or regulatory certifications. It is not an announcement of a report but a detailed internal control compliance document. This type of document fits best under Regulatory Filings (RNS) as it is a compliance-related filing that does not fit into other specific categories like Annual Report, Audit Report, or Management Reports.
2018-03-19 Chinese
独立董事候选人声明（魏素艳）
Board/Management Information Classification · 95% confidence The document is a detailed declaration by an independent director candidate of Beijing Shuanglu Pharmaceutical Co., Ltd. It contains statements about the candidate's qualifications, compliance with laws and regulations, and independence criteria. There are no financial statements, earnings data, or management discussion of financial results. The content is focused on governance and compliance related to board membership qualifications. This type of document fits best under Board/Management Information (MANG), as it relates to announcements about board members and their qualifications rather than financial reports or other filings.
2018-03-19 Chinese
独立董事候选人声明（苏志国）
Board/Management Information Classification · 95% confidence The document is a detailed declaration by an independent director candidate of Beijing Shuanglu Pharmaceutical Co., Ltd. It contains statements about the candidate's qualifications, compliance with various regulatory requirements, and independence criteria. There are no financial statements, earnings data, or management discussions. The content is focused on the candidate's eligibility and compliance with laws and regulations related to board membership. This type of document is related to board or management information, specifically announcements or declarations about board members or candidates. Therefore, the appropriate classification is Board/Management Information (MANG). The document length (6672 characters) supports it being a full declaration rather than a brief announcement or a report publication notice.
2018-03-19 Chinese
2017年年度报告摘要
Annual Report Classification · 100% confidence The document is titled "北京双鹭药业股份有限公司 2017 年年度报告摘要" which translates to "Beijing SL Pharmaceutical Co., Ltd. 2017 Annual Report Summary." It contains detailed financial data for the year 2017, including revenue, net profit, earnings per share, and asset information. It also includes comprehensive business descriptions, product information, shareholder data, and management discussion and analysis of the company's operations during the year. The document is over 13,000 characters long, indicating it is a substantive report rather than a brief announcement. The content aligns with the characteristics of an Annual Report, providing a full overview of company activity and financial performance for the fiscal year 2017. Therefore, the document should be classified as an Annual Report (10-K). FY 2017
2018-03-19 Chinese
关于2017年日常关联交易执行情况及2018年日常关联交易预计暨确认关联交易的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the execution of related party transactions for the year 2017 and the expected related party transactions for 2018 by Beijing Shuanglu Pharmaceutical Co., Ltd. It includes details about the nature of the transactions, amounts involved, related parties, independent directors' opinions, and supervisory board opinions. The document is structured as a formal announcement to shareholders and the public, detailing the company's related party transactions and compliance with regulatory requirements. It does not contain comprehensive financial statements or detailed financial performance data typical of annual or interim reports. It is not a full audit report, earnings release, or management discussion. The document is a regulatory announcement about related party transactions, which fits best under the category of Regulatory Filings (RNS) as it is a compliance disclosure and does not fit other more specific categories.
2018-03-19 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.